Castle biosciences enters collaboration and license agreement with scibase to develop diagnostic tests for dermatologic diseases

Friendswood, texas, june 16, 2025 (globe newswire) -- castle biosciences, inc. (nasdaq: cstl), a company improving health through innovative tests that guide patient care, today announced that it has entered into a collaboration and license agreement with scibase holding ab (“scibase”) utilizing scibase's electrical impedance spectroscopy technology which includes both desktop and point-of-care instruments. the initial goal of the collaboration is to advance the development of a diagnostic test that predicts flares in patients diagnosed with atopic dermatitis (ad).
CSTL Ratings Summary
CSTL Quant Ranking